rotavirus prophylaxis market, rotavirus prophylaxis market share, rotavirus prophylaxis market forecast, rotavirus prophylaxis market analysis, rotavirus prophylaxis industry, rotavirus prophylaxis global market
What is the current market size and future outlook for the rotavirus prophylaxis market?
The rotavirus prophylaxis market size has grown rapidly in recent years. It will grow from $9.05 billion in 2024 to $10.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.
The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $14.63 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.
Get Your Free Sample of The Global Rotavirus Prophylaxis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp
How have varous drivers impacted the growth of the rotavirus prophylaxis market?
The increasing vaccine courses are expected to propel the growth of the rotavirus prophylaxis market going forward. A vaccine course is a specific dose of vaccine that is meant to be given to a person to produce protection from a particular disease. The vaccine course dosage stimulates the immunological response, providing excellent protection against rotavirus infection. This increased immunity minimizes the risk of diseases and improves the vaccine’s overall efficacy. For instance, in January 2022, according to a report published by the United Nations International Children’s Emergency Fund (UNICEF), a US-based provider of humanitarian and developmental help to children, around 5.71 million courses of RV1-5 frozen rotavirus vaccine were produced 2022, with a projected increase to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were manufactured in 2022, with a projected rise to 6.13 million courses by 2028. Therefore, the increasing number of vaccines will drive the rotavirus prophylaxis market.
What are the primary segments of the rotavirus prophylaxis market?
The rotavirus prophylaxis market covered in this report is segmented –
1) By Treatment: Rotarix, Rotavac, Rotavin-M1, Oral Rehydration Fluid, Other Treatments
2) By Route of Administration: Oral, Parenteral, Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Rotarix: Single Dose, Multi-Dose
2) By Rotavac: Liquid Formulation, Freeze-Dried Formulation
3) By Rotavin-M1: Liquid Formulation, Freeze-Dried Formulation
4) By Oral Rehydration Fluid: Electrolyte Solutions, Glucose-Based Solutions
5) By Other Treatments: Supportive Care, Antidiarrheal Medications
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report
Which firms are leading the rotavirus prophylaxis market?
Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).
How will industry trends affect the trajectory of the rotavirus prophylaxis market?
Major companies operating in the rotavirus prophylaxis market are developing vaccines to meet customer requirements. Vaccine approvals involve a rigorous process that includes multiple development and testing stages. These approvals are essential in ensuring that vaccines are safe and effective for preventing this viral illness, particularly in infants and young children. For instance, in November 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company, announced that the Food and Drug Administration (FDA) had approved an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral), that prevents rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) in infants. The novel oral-dosing applicator-only presentation is entirely liquid and must not be reconstituted before use. ROTARIX lyophilized and liquid formulations are administered orally in a two-dose series, contain the same live, human-attenuated rotavirus strain and are made using comparable techniques.
Which geographic trends are shaping the rotavirus prophylaxis market, and which region has the highest market share?
North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Rotavirus Prophylaxis Market Report 2025 Offer?
The rotavirus prophylaxis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Rotavirus prophylaxis refers to the prevention of rotavirus infection through vaccination, which protects infants and young children from a highly infectious illness that causes stomach and bowel inflammation. The purpose is to protect from person from any severity.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13045
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
